Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect

British Journal of Pharmacology

Volumn 156, Issue 8, 2009, Pages 1218-1227

  Gomez Garre D ^a,b   Munoz Pacheco P ^b   Gonzalez Rubio M L ^b   Aragoncillo, P ^a   Granados, R ^c   Fernandez Cruz A ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Instituto Cardiovascular   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Anti atherogenic; Ezetimibe; Inflammation; Statin

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG EFFICACY; FEMUR; FIBROSIS; INFLAMMATION; MALE; MIGRATION INHIBITION; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; C-REACTIVE PROTEIN; CELL LINE; CELL MOVEMENT; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMORAL ARTERY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; MACROPHAGES; MALE; MONOCYTES; NF-KAPPA B; RABBITS; SIMVASTATIN;

EID: 68749102069     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00091.x     Document Type: Article

References (30)

1. Al-Shaer MH, Choueiri NE, Suleiman ES (2004). The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis 3 : 22. Available at: http://www.lipidworld.com/content/3/1/22 (DOI: 10.1186/1476-511X-3-22).
2. Bauvois B, Dauzonne D (2006). Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 26 : 88 130.
3. Davis HR Jr., Compton DS, Hoos L, Tetzloff G (2001). Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 21 : 2032 2038.
4. Fenton RG, Kung HF, Longo DL, Smith MR (1992). Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol 117 : 347 356.
5. Firla B, Arndt M, Frank K, Thiel U, Ansorge S, Täger M et al. (2002). Extracellular cysteines define ectopeptidase (APN, CD13) expression and function. Free Radic Biol Med 32 : 584 595.
6. Gómez-Garre D, Martín-Ventura JL, Granados R, Sancho T, Torres R, Ruano M et al. (2006a). Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients. Kidney Int 69 : 1237 1244.
7. Gómez-Garre D, Herraíz M, González-Rubio ML, Bernal R, Aragoncillo P, Carbonell A et al. (2006b). Activation of peroxisome proliferator-activated receptor-alpha and -gamma in auricular tissue from heart failure patients. Eur J Heart Fail 8 : 154 161.
8. Hernández-Presa MA, Bustos C, Ortego M, Tuñón J, Renedo G, Ruiz-Ortega M et al. (1997). Angiotensin-converting enzyme inhibition prevents arterial NF-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95 : 1532 1541.
9. Hernández-Presa MA, Ortego M, Tuñón J, Martín-Ventura JL, Mas S, Blanco-Colio LM et al. (2003). Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57 : 168 177.
10. Jialal I, Devaraj S, Singh U (2006). C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol 47 : 1379 1381.
11. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF et al. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 : 1431 1443.
12. Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, Jähne G et al. (2005). Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J Biol Chem 280 : 1306 1320.
13. Kuhlencordt PJ, Padmapriya P, Rützel S, Schödel J, Hu K, Schäfer A et al. (2009). Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 202 : 48 57.
14. Libby P, Aikawa M (2002). Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8 : 1257 1262.
15. Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM et al. (2007). Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50 : 852 858.
16. Moreno PR, Lodder RA, Purushothaman KR, Charash WE, O'Connor WN, Muller JE (2002). Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation 105 : 923 927.
17. Nachtigal P, Kopecky M, Solichova D, Zdansky P, Semecky V (2005). The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol 57 : 197 203.
18. Orsó E, Werner T, Wolf Z, Bandulik S, Kramer W, Schmitz G (2006). Ezetimib influences the expression of raft-associated antigens in human monocytes. Cytometry A 69 : 206 208.
19. Ridker PM, Stampfer MJ, Rifai N (2001). Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 : 2481 2485.
20. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. (2005). Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 : 20 28.
21. Riemann D, Kehlen A, Thiele K, Lohn M, Langner J (1997). Induction of aminopeptidase N/CD13 on human lymphocytes after adhesion to fibroblast-like synoviocytes, endothelial cells, epithelial cells, and monocytes/macrophages. J Immunol 158 : 3425 3432.
22. Ross R (1999). Atherosclerosis: an inflammatory disease. N Engl J Med 340 : 115 126.
23. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R et al. (2005). Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179 : 361 367.
24. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T et al. (1993). Role of aminopeptidase N (CD13) in tumor cell invasion and extracellular matrix degradation. Int J Cancer 54 : 137 143.
25. Santos AN, Langner J, Herrmann M, Riemann D (2000). Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. Cell Immunol 201 : 22 32.
26. Sasaki M, Bharwani S, Jordan P, Joh T, Manas K, Warren A et al. (2003). The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 305 : 78 85.
27. Srámek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR (2000). Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 35 : 699 706.
28. Sudhop T, Lütjohann D, Kodal A, Ige IM, Tribble DL, Shah S et al. (2002). Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 : 1943 1948.
29. Tani K, Ogushi F, Huang L, Kawano T, Tada H, Hariguchi N et al. (2000). CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis. Am J Respir Crit Care Med 161 : 1636 1642.
30. Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB et al. (1997). In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283 : 157 163.